EBV-specific T-cell immunotherapy ATA188 treats multiple sclerosis: positive results were achieved in all dose groups.

Multiple sclerosis (MS) is a demyelinating neuropathy in which the insulation (i.e. myelin) on the surface of nerve cells in the patient's brain or spinal cord is damaged and the signal transductive of the nervous system is impaired, leading to a range of possible symptoms that affect the patient's activity, mind, and even mental state.
positive progress in the treatment of multiple sclerosis (MS) with at Atara, a biopharmaceutical company.
ATA188 is an allogeneic EBV-specific T-cell immunotherapy.
latest data show that ATA188 has good tolerance in all four dosage groups, improving persistent disease at any point in time, and increasing numbers of patients exhibit continuous disability improvement (SDI) as doses increase.
the Ia Multi-Center Open Labeling Study for MS Patients aims to determine the safety, toerability and potential efficacy of ATA188.
patients were treated with four dose increments (5 x 106, 1 x 107, 2 x 107 and 4 x 107 cells), with 6 patients in the queue 1-3 and 7 patients in the queue 4.
patients in the queue 1-4 showed SDI at six months and continued to improve for 12 months.
.